BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34540896)

  • 1. Comprehensive Analysis of HDAC Family Identifies
    Fan Y; Peng X; Wang Y; Li B; Zhao G
    Front Mol Biosci; 2021; 8():720020. PubMed ID: 34540896
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Analysis of the Differential Expression and Prognostic Value of Histone Deacetylases in Glioma.
    Li J; Yan X; Liang C; Chen H; Liu M; Wu Z; Zheng J; Dang J; La X; Liu Q
    Front Cell Dev Biol; 2022; 10():840759. PubMed ID: 35359455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
    Xu S; Wang Z; Ye J; Mei S; Zhang J
    Front Oncol; 2021; 11():729103. PubMed ID: 34568059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analyses reveal the role of histone deacetylase genes in prognosis and immune response in low-grade glioma.
    Shen L; Li Y; Li N; Shen L; Li Z
    PLoS One; 2022; 17(10):e0276120. PubMed ID: 36227941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
    Ma W; Mei P
    World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
    Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
    Front Genet; 2021; 12():718717. PubMed ID: 34925438
    [No Abstract]   [Full Text] [Related]  

  • 8. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma.
    Zhang C; Yu R; Li Z; Song H; Zang D; Deng M; Fan Y; Liu Y; Zhang Y; Qu X
    Cancer Manag Res; 2019; 11():4971-4984. PubMed ID: 31213913
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Illustrating the biological functions and diagnostic value of transmembrane protein family members in glioma.
    Zhang Y; Zhang W; Yuan Q; Hong W; Yin P; Shen T; Fang L; Jiang J; Shi F; Chen W
    Front Oncol; 2023; 13():1145676. PubMed ID: 37064154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
    Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
    Front Oncol; 2021; 11():650153. PubMed ID: 34055619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
    Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
    Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
    [No Abstract]   [Full Text] [Related]  

  • 16. A Novel S100 Family-Based Signature Associated with Prognosis and Immune Microenvironment in Glioma.
    Hu Y; Song J; Wang Z; Kan J; Ge Y; Wang D; Zhang R; Zhang W; Liu Y
    J Oncol; 2021; 2021():3586589. PubMed ID: 34712325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication.
    Fan Y; Peng X; Li B; Zhao G
    Biomed Res Int; 2020; 2020():1872962. PubMed ID: 32964017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
    Luo C; Liu Z; Ye W; Liu F
    Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
    [No Abstract]   [Full Text] [Related]  

  • 19. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
    Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
    Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of histone deacetylases genes in the prognosis and immune infiltration of glioma patients.
    Shen L; Li Y; Li N; Shen L; Li Z
    Aging (Albany NY); 2022 May; 14(9):4050-4068. PubMed ID: 35545840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.